Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trinity BiotechTRIB -11.42%30 Equity-to-Asset is -0.68 as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 30/100 and a GF Value™ of $23.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 95.77% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Trinity Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-71.98 Mil. Trinity Biotech's Total Assets for the quarter that ended in Dec. 2025 was $105.17 Mil.
Therefore, Trinity Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -0.68.
The historical rank and industry rank for Trinity Biotech's Equity-to-Asset or its related term are showing as below:
TRIB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.68 Med: -0.01 Max: 0.44
Current: -0.68
During the past 13 years, the highest Equity to Asset Ratio of Trinity Biotech was 0.44. The lowest was -0.68. And the median was -0.01.
TRIB's Equity-to-Asset is ranked worse than 95.77% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs TRIB: -0.68
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Trinity Biotech Equity-to-Asset Related Terms
Trinity Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRIB vs STME, VVOS, AIDX: Equity-to-Asset Comparison
For the Medical Devices subindustry, Trinity Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Trinity Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a Equity-to-Asset of -0.68 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #815 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 95.8%.
Is Trinity Biotech's Equity-to-Asset too high?
Trinity Biotech's current Equity-to-Asset is -0.68. Based on the distribution chart, Trinity Biotech ranks #815 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Equity-to-Asset compare to STME and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #815 out of 851 companies for Equity-to-Asset. This places Trinity Biotech in the lower half of its industry. The industry median Equity-to-Asset is 0.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current Equity-to-Asset is -0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $23.24, compared to a current price of $11.01 — trading 52.6% below its estimated fair value. The current Equity-to-Asset is -0.68. Trinity Biotech's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Equity-to-Asset is -0.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $11.01 is trading 52.6% below its estimated GF Value™ of $23.24.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Equity-to-Asset: -0.68
GF Value™: $23.24 vs. price of $11.01 (52.6% below fair value)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
30GF Score
Get the complete analysis for TRIB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
